A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Hendrickson Andrea E. Wahner; Menefee Michael E.; Hartmann Lynn C.; Long Harry J.; Northfelt Donald W.; Reid Joel M.; Boakye-Agyeman Felix; Kayode Olumide; Flatten Karen S.; Harrell Maria I.; Swisher Elizabeth M.; Poirer Guy G.; Satele Daniel; Allred Jake; Lensing Janet L.; Chen Alice; Ji Jiuping; Zang Yiping; Erlichman Charles; Haluska Paul; Kaufmann Scott H.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

【24h】

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

机译：Poly（ADP-Ribose）聚合酶抑制剂Veliparib的I临床试验和实体肿瘤患者的每周拓扑替康

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To determine the dose limiting toxicities (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative studies were included to assess the impact of topotecan and veliparib on poly(ADP-ribose) levels in peripheral blood mononuclear cells, serum pharmacokinetics of both agents, and potential association of germline repair gene mutations with outcome.

机译：None

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2018年第4期|共9页
作者
Hendrickson Andrea E. Wahner; Menefee Michael E.; Hartmann Lynn C.; Long Harry J.; Northfelt Donald W.; Reid Joel M.; Boakye-Agyeman Felix; Kayode Olumide; Flatten Karen S.; Harrell Maria I.; Swisher Elizabeth M.; Poirer Guy G.; Satele Daniel; Allred Jake; Lensing Janet L.; Chen Alice; Ji Jiuping; Zang Yiping; Erlichman Charles; Haluska Paul; Kaufmann Scott H.;
展开▼
作者单位

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin Ponte Vedra FL USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin Scottsdale AZ USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Univ Washington Seattle WA 98195 USA;

Univ Washington Seattle WA 98195 USA;

Univ Laval Quebec City PQ Canada;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

NCI DCTD Bethesda MD 20892 USA;

NCI DCTD Bethesda MD 20892 USA;

NCI DCTD Bethesda MD 20892 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

Mayo Clin 200 First St SW Rochester MN 55905 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label,phase Ⅰ dose escalation and dose expansion trial [J] . Yan Song, Jinwan Wang, Xiubao Ren, 中国癌症研究（英文版） . 2021,第001期
2. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors [J] . Zhong-min YANG, Ao ZHANG, Jin-xue HE, 中国药理学报：英文版 . 2017,第007期
3. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy [J] . Wen-hua CHEN, Jian LI, Shan-shan SONG, 中国药理学报：英文版 . 2017,第011期
4. The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer [J] . Jeanny B Aragon-Ching 亚洲男性学杂志（英文版） . 2016,第004期
5. Poly (ADP-ribose) polymerase inhibitor:an evolving paradigm in the treatment of prostate cancer [J] . Jingsong Zhang 亚洲男性学杂志（英文版） . 2014,第003期
6. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors [J] . Hendrickson Andrea E. Wahner, Menefee Michael E., Hartmann Lynn C., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第4期

机译：Poly（ADP-核糖）聚合酶抑制剂Veliparib的I临床试验和实体肿瘤患者的每周拓扑顿
7. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors [J] . LoRusso Patricia M., Li Jing, Burger Angelika, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第13期

机译：晚期实体瘤患者中聚（ADP-核糖）聚合酶（PARP）抑制剂维利巴利（ABT-888）与依立替康联用的I期安全性，药代动力学和药效学研究
8. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. [J] . Jens Samol, Malcolm Ranson, Edwina Scott, Investigational new drugs. . 2012,第4期

机译：聚（ADP-核糖）聚合酶（PARP）抑制剂olaparib（AZD2281）与托泊替康联合治疗晚期实体瘤患者的安全性和耐受性：I期研究。
9. DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1(PARP1)INHIBITORS FOR THE TREATMENT OF SOLID TUMORS [C] . J.Priyancy, D.P.Bhumika Conference on Drug Design and Discovery Technologies . 2020

机译：用于治疗实体肿瘤的新型聚ADP-核糖聚合酶1（PARP1）抑制剂的设计与合成
10. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity [D] . Velagapudi, Uday Kiran. 2019

机译：聚（ADP-核糖）聚合酶抑制剂的设计与合成：腺苷袋结合基序附录对3-氧代-2,3-二氢苯并呋喃-7-甲酰胺对效力和选择性的影响
11. Phase I safety pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors [O] . Patricia M. LoRusso, Jing Li, Angelika Burger, -1

机译：聚（ADP-核糖）聚合酶（PARP）抑制剂veliparib（ABT-888）与伊立替康联合治疗晚期实体瘤的I期安全性药代动力学和药效学研究
12. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors [O] . Andrea E. Wahner Hendrickson, Michael E. Menefee, Lynn C. Hartmann, 2017

机译：Poly（ADP-核糖）聚合酶抑制剂Veliparib的I临床试验和实体肿瘤患者的每周拓扑顿
13. Mechanisms of Poly(ADP-ribose) polymerase Catalysis; Mono-ADP-ribosylation of Poly(ADP-ribose) polymerase at Nanomolar Concentrations of NAD [R] . Bauer, P. I., Hakam, A., Kun, E. 1986

机译：聚（aDp-核糖）聚合酶催化机制;纳摩尔浓度的NaD的聚（aDp-核糖）聚合酶的单-aDp-核糖基化

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅